143 related articles for article (PubMed ID: 23791435)
1. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center.
Grassi P; Verzoni E; Mariani L; De Braud F; Coppa J; Mazzaferro V; Procopio G
Clin Genitourin Cancer; 2013 Dec; 11(4):484-8. PubMed ID: 23791435
[TBL] [Abstract][Full Text] [Related]
2. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
3. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R; Cartenì G; Sternberg CN; Milella M; Santoni M; Di Lorenzo G; Ortega C; Sabbatini R; Ricotta R; Messina C; Lorusso V; Atzori F; De Vincenzo F; Sacco C; Boccardo F; Valduga F; Massari F; Baldazzi V; Cinieri S; Mosca A; Ruggeri EM; Berruti A; Cerbone L; Procopio G
Eur J Cancer; 2013 Jun; 49(9):2134-42. PubMed ID: 23518211
[TBL] [Abstract][Full Text] [Related]
7. Survival data justifies resection for pancreatic metastases.
Strobel O; Hackert T; Hartwig W; Bergmann F; Hinz U; Wente MN; Fritz S; Schneider L; Büchler MW; Werner J
Ann Surg Oncol; 2009 Dec; 16(12):3340-9. PubMed ID: 19777190
[TBL] [Abstract][Full Text] [Related]
8. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma?
Cetin B; Berk V; Kaplan MA; Afsar B; Tufan G; Ozkan M; Isikdogan A; Benekli M; Coskun U; Buyukberber S
Clin Genitourin Cancer; 2013 Jun; 11(2):141-8. PubMed ID: 23083797
[TBL] [Abstract][Full Text] [Related]
9. [Impact of surgery in the management of pancreatic metastases of renal cell cancer].
Bertrand J; Saint-Aubert B; Joly E; Philippe C; Quenet F; Carrere S; Rouanet P; Domergue J
Prog Urol; 2014 Apr; 24(5):307-12. PubMed ID: 24674337
[TBL] [Abstract][Full Text] [Related]
10. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
11. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
12. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.
Soerensen AV; Donskov F; Hermann GG; Jensen NV; Petersen A; Spliid H; Sandin R; Fode K; Geertsen PF
Eur J Cancer; 2014 Feb; 50(3):553-62. PubMed ID: 24215846
[TBL] [Abstract][Full Text] [Related]
13. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival after pancreatic resection for renal cell carcinoma metastasis.
Schwarz L; Sauvanet A; Regenet N; Mabrut JY; Gigot JF; Housseau E; Millat B; Ouaissi M; Gayet B; Fuks D; Tuech JJ
Ann Surg Oncol; 2014 Nov; 21(12):4007-13. PubMed ID: 24879589
[TBL] [Abstract][Full Text] [Related]
15. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients.
Procopio G; Testa I; Verzoni E; Iacovelli R; Grassi P; Galli G; De Braud F; Saravia D; Salvioni R
Oncology; 2015; 88(3):133-8. PubMed ID: 25377648
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic metastasis from clear cell renal cell carcinoma: outcome of an aggressive approach.
Benhaim R; Oussoultzoglou E; Saeedi Y; Mouracade P; Bachellier P; Lang H
Urology; 2015 Jan; 85(1):135-40. PubMed ID: 25530375
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic metastasis of renal cell carcinoma: presentation, treatment and survival.
Faure JP; Tuech JJ; Richer JP; Pessaux P; Arnaud JP; Carretier M
J Urol; 2001 Jan; 165(1):20-2. PubMed ID: 11125354
[TBL] [Abstract][Full Text] [Related]
19. Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.
Parmar A; Soliman H; Sahgal A; Bjarnason GA
Clin Genitourin Cancer; 2020 Jun; 18(3):e224-e232. PubMed ID: 32139300
[TBL] [Abstract][Full Text] [Related]
20. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
